Portal de Periódicos da CAPES

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

2020; American Association of Immunologists; Volume: 205; Issue: 4 Linguagem: Inglês

10.4049/jimmunol.2000583

1550-6606

Wafaa B. Alsoussi, Jackson S. Turner, James Brett Case, Haiyan Zhao, Aaron J. Schmitz, Julian Q. Zhou, Rita E. Chen, Tingting Lei, Amena A. Rizk, Katherine M. McIntire, Emma S. Winkler, Julie M. Fox, Natasha M. Kafai, Larissa B. Thackray, Ahmed O. Hassan, Fatima Amanat, Florian Krammer, Corey T. Watson, Steven H. Kleinstein, Daved H. Fremont, Michael Diamond, Ali H. Ellebedy,

Viral gastroenteritis research and epidemiology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.